Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://www.springerlink.com/index/pdf/10.1532/IJH97.04013
Reference94 articles.
1. Tauchi T, Broxmeyer HE. BCR/ABL signal transduction. Int J Hematol. 1995;61:105-112.
2. Konopka JB, Watanabe SM, Witte ON. An alternation of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37:1035-1042.
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340: 1330-1340.
5. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131: 207-219.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia;Experimental Hematology;2013-05
2. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia;Blood;2011-09-22
3. Interferon alpha for Treatment of Chronic Myeloid Leukemia;Current Drug Targets;2011-03-01
4. Transcription and signalling pathways involved in BCR–ABL-mediated misregulation of 24p3 and 24p3R;The EMBO Journal;2009-02-19
5. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses;Journal of Molecular Medicine;2007-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3